NCT05889299View on ClinicalTrials.gov

Study of the Safety and Efficacy of OMS906 in Patients With Paroxysmal Nocturnal Hemoglobinuria

PHASE1UnknownINTERVENTIONAL

Enrollment

10

Participants

Timeline

Start Date

December 9, 2022

Primary Completion Date

October 30, 2023

Study Completion Date

June 30, 2024

Conditions

Paroxysmal Nocturnal Hemoglobinuria

Interventions

DRUG

OMS906 study drug

OMS906 study drug dose repeat-dose 5mg/kg SC administration at 4-week intervals

Trial Locations (1)

Unknown

RECRUITING

Omeros Investigational Site, Kyiv

Sponsors

Lead Sponsor

Omeros Corporation

All Listed Sponsors

lead

Omeros Corporation

INDUSTRY

NCT05889299 - Study of the Safety and Efficacy of OMS906 in Patients With Paroxysmal Nocturnal Hemoglobinuria | Biotech Hunter | Biotech Hunter